Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

Jae Hong Seo, Sang Cheul Oh, Cheul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Ae Ree Kim, Jae Bok Lee, Bum Hwan Koo

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number2
DOIs
Publication statusPublished - 2007 Feb

Keywords

  • Cisplatin
  • Gemcitabine
  • Metastatic breast cancer
  • Taxane resistant

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer'. Together they form a unique fingerprint.

Cite this